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Beneficence as a Principle in Human Research 
Abstract 
Beneficence is one of the four principles that form the basis of the National 
Statement.  The aim of this paper is to explore the philosophical development of 
this principle and to clarify the role that beneficence plays in contemporary 
discussions about human research ethics.  By examining the way that guidance 
documents, particularly the National Statement, treats beneficence we offer 
guidance to researchers and human research ethics committee members on the 
practical application of what can be conceptually difficult principle. 
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Beneficence as a Principle in Human Research 
Introduction 
Beneficence is one of the four values and principles on which the National 
Statement on Ethical Conduct in Human Research (National Statement) is 
founded.  Beneficence is a moral ideal, a principle which promotes good or 
charitable outcomes, over and above those imposed by duty.  Beneficence 
echoes both utilitarianism, as one benchmark for good outcomes, and 
deontology in the promotion of the value of charitable works.  
The purpose of this paper is to clarify the role that beneficence plays in 
discussions about human research ethics.  Applying beneficence in human 
research involves identifying and assessing the risks and benefits of a proposed 
human research project. These considerations extend beyond the individual and, 
so, researchers ought to reflect on the impact of their work at both the individual 
level and more generally.  
 
This paper provides both researchers and human research ethics committee 
(HREC) members with guidance on the application of beneficence in the design, 
review and conduct of ethical human research. This guidance recognises the 
place of beneficence and its relationship with the other principles contained 
within the National Statement. 
HRECs should be prepared to enter into discussions with researchers to reach a 
shared understanding of how this principle can be promoted within a project - 
both at an individual and at a broader level.  Finally, we offer some practical 
suggestions about how these discussions might be improved.  
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What is Beneficence? 
“Beneficence is always free, it cannot be extorted by force, the mere 
want of it exposes to no punishment; because the mere want of 
beneficence tends to do no real positive evil” – [Smith, 1790; p70] 
Beneficence, or a similar ideal, is a consideration in many ethical theories.  As a 
principle, beneficence is supported through both consequentialist and 
deontological argument [Munson, R., 2008; p 772], as well as having links to 
both virtue ethics [Frankena, 1982] and principle-based bioethics [Beauchamp & 
Childress 2013].  Beneficence is often seen as a virtuous characteristic for a 
person to demonstrate through promoting good or charitable outcomes, such as 
in the parable of the Good Samaritan [Luke 10:25-37 KJV].  Hume [Sect. 4 part 
1] described beneficence as a “social virtue” because it “promotes the good of 
the community” and not just those individuals who benefit directly. 
Beneficence is one of the drivers of any public health system:  the ideal that 
people within a society should promote health in general as a social good and, 
more specifically, provide a level of health-care for the disadvantaged in society 
[Faden & Shabaya, 2010].   
To do no harm, is not the same as actively providing benefit.  The term 
beneficence refers to actions which help others.  A beneficent act is one which 
promotes the betterment of others for altruistic reasons.  Beauchamp and 
Childress (2013) refer to this principle as positive beneficence and break it down 
into three components: to prevent evil or harm; to remove evil or harm; and to 
do or promote good (p151).  The implementation of each of these components 
requires researchers to take action by helping others (p152). They then 
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distinguish positive beneficence from another meaning of beneficence, namely, 
utility, which they briefly describe as requiring “that benefits risks and costs” be 
balanced in order to achieve the “best overall results” (p202).  It is this meaning 
of beneficence that is closer to the way that the principle is understood and 
relied on in human research ethics and in the National Statement. 
As a principle which promotes good in society, the moral ideal of beneficence 
ought to be present in all human research projects to ensure that the way that 
participants are treated within research is as beneficent as can be achieved.  The 
National Statement builds on this philosophical basis to provide practical 
guidance on the application of this little considered principle.   
 
What does beneficence mean within human research? 
The context of human research compels a re-assessment of the scope of 
beneficence.  The good or benefit that is essential to beneficence becomes the 
good or benefit of the research.  However, the assessment of that benefit needs 
to take into account the non-benefit features of the context - the burdens and 
risks to participants.  This construction is what Beauchamp and Childress refer to 
as the principle of utility [Beauchamp & Childress 2013].  
Acting beneficently in human research thus requires some assessment of both 
the intended benefits of the research and of the risks to which participants will 
be exposed.  These assessments are sometimes referred to as balancing the 
risks and benefits or finding a favourable risk-benefit ratio.  However, both the 
Belmont Report and the National Statement ask researchers to justify the 
inclusion of selected populations.  
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Unconfined by the human research context, a characteristic of beneficence is 
that, unlike the other principles on which the National Statement is based, the 
absence of beneficence does no harm.  It can easily be demonstrated that the 
absence of respect, justice or scientific merit can be harmful in many ways.  Mill 
establishes a distinction between beneficence and justice in that justice 
correlates with specific rights, whilst individuals can make no claim to a right to 
beneficent acts [Mill, 1879; Chap. 5].  The absence of beneficence is a subtler 
ethical flaw in a research proposal and while there is an obligation imposed on 
researchers to act beneficently, how that obligation is fulfilled requires careful 
judgment by the researcher.  
 
The position set out in the Nuremberg Code (1949) was that research ought to 
promote a greater good.  Rhodes (2005) points out that, from the 1987 
Declaration of Helsinki, the World Medical Association began to align the 
perception of doing good in research with beneficence towards participants.  This 
equates potential harms of research more closely with non-maleficence (p20) 
than with “the humanitarian importance of the problem to be solved” 
[Nuremberg Code, point 6].   
 
The principle of beneficence should be overtly discussed when considering the 
ethical acceptability of a proposed human research project.  The overall good 
that beneficence may refer to is not always apparent.  However, where there is 
little benefit for individual participants, HREC members and researchers should 
look for the promotion of a greater good.  Where there is a question as to 
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whether risks to participants are justified only by benefits for them, there would 
need to be a commensurate greater good being served to justify those risks.   
For human research to be ethically defensible there must be a positive 
justification of the project.  Beneficence, and questions of what constitutes a 
benefit or a risk within a research project, can be amongst the most subjective 
that face decision-makers within human research ethics. For this reason, it is 
vital that the risks and benefits are discussed explicitly so as to include and 
evaluate multiple viewpoints.  The role of the HREC lay member (National 
Statement 5.1.30 (b) is brings added depth and community context to this 
discussion by providing a perspective which is distinct from the researcher or 
subject expert.  An important consideration of beneficence in human research is 
that of public perception of potential risks and benefits. 
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The emerging recognition of beneficence in human research ethics 
The selection of beneficence as one of the foundation values of the National 
Statement is likely to have followed the developing influence of principlism in the 
arena of bioethics, where beneficence is a recurrent issue in modern literature 
on biomedical ethics, and from its use in the Belmont Report 
The Belmont Report commences the discussion of beneficence with the following 
description: 
Beneficence. -- Persons are treated in an ethical manner not only by 
respecting their decisions and protecting them from harm, but also by 
making efforts to secure their well-being. Such treatment falls under 
the principle of beneficence. The term "beneficence" is often 
understood to cover acts of kindness or charity that go beyond strict 
obligation. In this document, beneficence is understood in a stronger 
sense, as an obligation. Two general rules have been formulated as 
complementary expressions of beneficent actions in this sense: (1) do 
not harm and (2) maximize possible benefits and minimize possible 
harms. 
Following this introduction, and in implicit recognition of the same distinction 
that is made by Beauchamp and Childress, the Report continues: 
Learning what will in fact benefit may require exposing persons to risk. 
The problem posed by these imperatives is to decide when it is justifiable 
to seek certain benefits despite the risks involved, and when the benefits 
should be foregone because of the risks. 
The obligations of beneficence affect both individual investigators and 
society at large, because they extend both to particular research projects 
and to the entire enterprise of research. In the case of particular projects, 
investigators and members of their institutions are obliged to give 
forethought to the maximization of benefits and the reduction of risk that 
might occur from the research investigation. In the case of scientific 
research in general, members of the larger society are obliged to 
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recognize the longer term benefits and risks that may result from the 
improvement of knowledge and from the development of novel medical, 
psychotherapeutic, and social procedures. 
At the more applied level, of the ethical acceptability of specific research 
projects, the Report again emphasise the fact that beneficence has both 
individual and societal dimensions highlighting that:  
 ... interests other than those of the subject may on some occasions be 
sufficient by themselves to justify the risks involved in the research, so 
long as the subjects' rights have been protected. Beneficence thus 
requires that we protect against risk of harm to subjects and also that we 
be concerned about the loss of the substantial benefits that might be 
gained from research. 
The International Ethical Guidelines for Biomedical Research Involving Human 
Subjects developed by the Council for International Organizations of Medical 
Sciences (CIOMS) in collaboration with the World Health Organization (WHO) 
describe state that 
 
Beneficence refers to the ethical obligation to maximize benefits and to 
minimize harms. This principle gives rise to norms requiring that the risks 
of research be reasonable in the light of the expected benefits, that the 
research design be sound, and that the investigators be competent both 
to conduct the research and to safeguard the welfare of the research 
subjects. 
 
 
How does the National Statement on Ethical Conduct in Human Research 
Portray Beneficence? 
The National Statement establishes that one of the hallmarks of ethical research 
is that the research team acts beneficently towards participants.  One of the 
determinations to be made by an HREC each time it considers a research 
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application is: “how does this research project demonstrate beneficence?”  The 
perspective of participants should also be a consideration.  Volunteers often 
participate in research for the benefit of others and with no expectation of a 
personal gain [Woods & McCormack, 2013].  Committees should include 
altruistic participation as a factor when determining beneficence within a 
proposal. 
Instead of expressing the beneficence in terms of whether there is an acceptable 
balance between the intended benefits and the risks, or that there is an 
acceptable risk-benefit ratio, the National Statement, in common with the 
Belmont Report, states, at paragraph 1.6, that the requirement of beneficence is 
better expressed in terms of justification: 
The likely benefit of the research must justify any risks of harm or 
discomfort to participants. 
Beneficence is described in the National Statement in the following terms (page 
11): 
Researchers exercise beneficence in several ways: in assessing and 
taking account of the risks of harm and the potential benefits of 
research to participants and to the wider community; in being 
sensitive to the welfare and interests of people involved in their 
research; and in reflecting on the social and cultural implications of 
their work. 
This description indicates that there are several elements to beneficence.   
The importance of beneficence in human research lies in the fact that human 
research requires participants to be exposed to some unknown effects and 
therefore to some risk of harm; whether physical, psychological or emotional.  
Doing good in research would, in a broader sense of beneficence, commonly 
mean conducting research that is beneficial or at least likely to be so. However, 
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because a determination of that good cannot ignore risks to which participants 
may be exposed, the simple meaning of the value, doing good, is not sufficient.   
Introducing an obligation on researchers to ensure that projects demonstrate the 
value, or principle, of beneficence arguably replaces an aspirational moral ideal 
with an enforceable moral obligation [Beauchamp; 2013].  However, it could 
also be argued that the human research endeavour is reliant on the charity of 
participants and that researchers should reciprocate by ensuring a benefit from 
the research. 
 
Beneficence and the Principles of Research Merit and Integrity, Justice 
and Respect 
The stated purpose of the National Statement is to promote ethically good 
human research, that is, research that is of benefit to the community and in 
which participants are accorded the respect and protection due to them.  For 
research to have such benefit, it needs to have merit by being base don current 
literature, adopting appropriate methods and being conducted by competent 
researchers.  In this way the National Statement, relates beneficence to 
research merit and echoes the statements in the Belmont report that 
beneficence in research relates not only to the impacts of the particular project 
being assessed but also how it promotes “the entire enterprise of research”.  
The utility aspect of beneficence, which justifies risks by reference to the 
expected benefits to the participants and/or the community, is only one aspect 
of the consideration of beneficence.  Beneficence should not be considered as a 
one-way street with consideration only given to the actions of researchers.  As 
with all human research, each project should be considered on its merits.  The 
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principle of beneficence shares strong ties with respect, in particular respect for 
autonomy.  The Belmont Report recognised this in stating that is beneficence is 
demonstrated by not only “respecting [participants’] decisions and protecting 
them from harm, but also by making efforts to secure their well-being” [Belmont 
B2]. Opportunities within research for participants to behave altruistically, 
through accepting greater risks, should not be dismissed out of hand.  There 
may well be instances where the project would fail a simple test of the 
justification of risks to participants but where important research questions are 
investigated; questions which benefit a community or society in general.   An 
example of this might be where the decision of a participant is counter to the 
participant’s self-interest.  This may be the case in phase 0 or phase 1 clinical 
trials for a pharmaceutical where the effects of the drug in humans is largely 
unknown. 
Beneficence may be a particularly difficult principle to promote when projects are 
conducted through commercial enterprises or research institutes.  For each and 
every human research project to be seen as promoting the general good above 
and beyond the scope of what a research intensive enterprise might otherwise 
be expected to achieve seems to be unrealistic.  It would be reasonable to 
expect commercial research programmes to, at least, do no harm:  that is, to 
demonstrate non-maleficence but, it appears to be unreasonable to expect them 
to actively promote good outcomes that exceed the ethical duties and 
obligations that society imposes on other corporate citizens.  However, 
commercial research organisations, particularly in the pharmaceutical industry 
are a complex case in that, although the billions of dollars of profit made by the 
industry each year are only possible through the risks taken by volunteer 
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participants in research, the benefit to the community as a whole of the products 
that generate those profits merits careful assessment. 
On a lesser scale, the same may well be said for research within many 
institutions such as hospitals, aged-care facilities, schools or prisons.  Research 
within these facilities may well contribute to better practices or conditions within 
the facilities and research may still meet the criterion of research merit but not 
clearly achieve the principle of justice as fairness.  It is the clients that take the 
risk for the betterment of the institution.  For example, research into better 
teaching practices may lead to improvements in future practices and benefits for 
future students but it is those students within the project that bear the burden 
and the risk, without the direct benefits.   
This type of research may be seen as having scientific merit and integrity; it 
may treat participants with respect and it may demonstrate a level of social 
justice but not distributive justice.  However, in seeking to demonstrate 
beneficence in such a project, it will often be insufficient to solely rely on 
demonstrating an overall good to justify its conduct.  The continuing tension in 
beneficence between benefits that accrue to society and those that accrue to the 
individual participants can be difficult to balance.  Whether, in any human 
research project, beneficence is demonstrated by a positive benefit to those who 
bear the burdens of participation, or a positive benefit to members of a 
community, or of society generally or, indeed, all of these, is a consideration 
unique to each application.  It may be unrealistic to expect that every human 
research project is beneficial to the participants that bear the risks.  Where a 
project cannot demonstrate sufficient benefits to the participants, it must be 
justifiable through the benefits it brings to a community or society.  These 
benefits will need to be both clearly demonstrated and substantial. 
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Participant Welfare and Interests 
As we have shown, identification of risks to participants and benefits to them 
and/or a wider community are central to demonstrating beneficence. 
What is risk? 
The National Statement defines risk as “a potential for harm, discomfort or 
inconvenience” [National Statement, 2.1].  Risk is considered in terms of what 
the potential harm might be, the likelihood that harm will occur if that risk is 
realised and the severity of the consequences that may follow participation.  The 
assessment of potential harm inevitably involves the exercise of judgment 
[National Statement; 2.1: p15].  Circumstances which may be seen as a 
problem or issue for one participant, may not be seen as an issue for others 
under the same conditions.  The guidance in the National Statement is that 
“[w]here a person’s reactions exceed discomfort and become distress, they 
should be viewed as harms”.  This can be difficult or even impossible to predict 
when the project is being assessed by an HREC.  However, if a situation is 
identified as a presenting a potential for harm, the researcher’s responsibility is 
to provide the HREC with a justification and a plan to mitigate the risk and 
manage any harm that may result from the materialisation of a risk. 
Chapter 2.1 of the National Statement sets out the following kinds of potential 
harms in human research: 
 physical harms: including injury, illness, pain; 
 psychological harms: including feelings of worthlessness, distress, guilt, 
anger or fear related, for example, to disclosure of sensitive or 
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embarrassing information, or learning about a genetic possibility of 
developing an untreatable disease; 
 devaluation of personal worth: including being humiliated, manipulated or 
in other ways treated disrespectfully or unjustly; 
 social harms: including damage to social networks or relationships with 
others; discrimination in access to benefits, services, employment or 
insurance; social stigmatisation; and findings of previously unknown 
paternity status; 
 economic harms: including the imposition of direct or indirect costs on 
participants; 
 legal harms: including discovery and prosecution of criminal conduct. 
 
How is Risk Assessed? 
This aspect of beneficence in human research is amongst the most 
subjective.  What is considered a risk by some people in some instances may 
not be seen as a risk in others, or by other people.  Because personal distress 
is such a highly subjective matter and may be influenced by many personal, 
cultural, physical or emotional factors, both researchers and HREC members 
should take a broad, realistic and informed view of possible risks.  At the 
same time, HREC members need to remember that the purpose of the review 
is not to eliminate risk but to see that it is adequately minimised and 
effectively managed. It is incumbent on researcher-applicants to demonstrate 
an understanding of the principle of beneficence and show how it will be 
promoted through their research project.  It should not be for the HREC to 
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imagine how the project may: prevent evil or harm; remove evil or harm; or 
do or promote good (Beauchamp and Childress, 2013, p151). 
Researchers and HREC members ought to take into account the population 
being researched, the skills and experience of the research team, as well as 
what is being asked of the participants when assessing risks.  The onus is on 
the researcher to make the case that the risks of the research are justified by 
the likely benefits and that the research is ethically acceptable.  It makes the 
job of the HREC member, and by extension that of the researcher, easier 
when the risks and benefits are expressed in terms of those affected.  For 
this purpose, there are a number of aspects to the research which should be 
considered during the application process.  
First, the research team must demonstrate an appropriate understanding of 
the research population.  This can be done by being explicit about the 
existing relationship between the researchers and participants, their culture, 
sub-culture or population, as appropriate.  Part of the purpose of this is to 
show the HREC that the researchers understand what importance participants 
might place on risks and benefits (National Statement, paragraphs 2.1.4, 
2.1.5).  The HREC should be in a position to take a disinterested view of the 
research, where the researcher may be too personally involved in the project 
and be influenced by that closeness.   Where a committee is in doubt about 
their ability to properly assess the risks or benefits of an application they 
should seek unbiased expert advice. 
Second, the research team ought to demonstrate that they have sufficient 
experience to be able to understand, assess and mitigate the existence and 
relevance of risk.  The applicability of previous research experience may not 
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be immediately obvious, so that any application for ethical approval should 
make explicit how the experience of the team relates to the current project.  
Researchers should not rely on the committee to be able to extrapolate from 
one research project to another, particularly when using novel 
methodologies.  It is sometimes difficult to identify all of the risks involved in 
a research project in the planning phase.  So, the research team needs to 
ensure that the HREC can be confident that they will be able to identify 
emergent risks as they occur and to appropriately manage them. 
As identified earlier and as the National Statement makes clear, beneficence 
ought not to be synonymous with risk-benefit ratios.  To approach the 
principle in that manner would be to reduce a morally complex question to 
something akin to an accounting exercise.  The nature of beneficence is to 
promote ‘good’ through positive action.  Applicants need to be explicit about 
potential opportunities within their project that will promote personal well-
being, personal or cultural autonomy or social justice.  Not all projects will 
accrue benefits so widely, and some areas of research offer greater scope for 
beneficence in this sense, but where they exist these opportunities should be 
pursued. 
 
Dealing with Incidental Findings 
Planning for incidental findings 
There can be a risk that information will be discovered during the research which 
is not related to the project but may be of importance to a participant.  The 
possibility of incidental findings should be considered in the development of the 
project. Often there is no real risk of unintentionally discovering anything of 
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import to participants, but in projects which include genetic or diagnostic testing 
and extended interviews on personal relationships or other personally sensitive 
issues, there can be a reasonable chance that something unexpected and of 
significance to the individual may be uncovered. 
The question of incidental discovery ought to be considered as part of the risk-
benefit considerations at the very start of planning a project.  It is important 
that the possibility of incidental discoveries be considered at the outset so that 
the consenting process can include a discussion with participants as to how 
these discoveries might be handled should they arise, under what conditions the 
information might be disclosed and to whom.  As part of the information that is 
provided to them, participants must be made aware of any mandatory reporting 
that might be necessitated from incidental discoveries.  Despite appropriate 
attention to foreseeable incidental discoveries, sometimes other unforeseen and 
unexpected information is uncovered during the course of the research.  Where 
discoveries affect the ethical nature of the research, or where the researchers 
are unsure of how they should best proceed, they should seek guidance from the 
approving ethics committee. 
These views are substantially supported by the recommendations in the 2013 
report of the Presidential Commission for the Study of Bioethical Issues:  
ANTICIPATE and COMMUNICATE:  Ethical Management of Incidental and 
Secondary Findings in the Clinical, Research, and Direct-to-Consumer Contexts.  
In relation to the disclosure in the consent process, the Commission 
recommended not only that researchers should inform participants of the scope 
of potential incidental or secondary findings but also whether and how these will 
be disclosed and whether and how they can opt-out of receiving certain types of 
findings.  If researchers object on ethical grounds to allowing participants to opt-
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out of receiving some incidental findings, such as those that raise life 
threatening possibilities, the Commission indicated that researchers could 
exclude such participants.  
The Commission also recommended that researchers develop and seek ethical 
approval of a plan for evaluating and managing incidental findings which could 
not be anticipated. Where necessary, they may need to seek advice from clinical 
or other experts on the significance of such findings.  The features of this plan 
should be disclosed to participants during the consent process.  Lastly, the 
Commission recommended that researchers, as opposed to clinicians, do not 
have a general ethical obligation to look for secondary findings and should 
carefully consider whether they should do so.   
Dealing with incidental findings 
In fulfilling a general duty to act beneficently, or a more urgent duty to rescue, 
the researcher should be able to articulate foreseeable incidental discoveries in 
terms of the level of risk to participants. Researchers and ethics committees 
sometimes struggle with the question of how incidental findings ought to be 
managed.  There is no specified set of rules by which researchers are obliged to 
manage information that is unintentionally discovered about participants or their 
circumstances during the course of a research project, except in the context of 
genetic research.  The National Statement does not make any direct reference to 
this issue.  HRECs will often rely on the informed consent process, particularly on 
data management aspects to ensure that participants understand what they may 
or may not discover through participation.  Researchers ought to manage data, 
including incidental findings, in the manner consistent with what they tell the 
participants. A minimalist view of disclosure would be to act on only those 
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discoveries where there was an obligation to act (Miller, Mello & Joffe 2008, 
p292), such as; the discovery of suspected child abuse or other event to which a 
mandatory reporting requirement applies.  However, given that a relationship 
exists between the researcher and the participant, the duty on the researcher to 
act beneficently should go beyond the minimalist approach.  How far beyond 
that may well depend on a number of factors, including: 
 The closeness of the association between the researcher and participant.  
Consideration ought to be given to not only existing relationships but also 
to the nature of the relationship that may develop as a function of the 
research.  There would be a different level of obligation arising from 
interviews as opposed to a clinician conducting a lengthy trial of treatment 
for people who are dependent on medical care.   
 The significance that the individual may place on the discovered 
information.  The helpfulness principle described by Miller, Mello & Joffe 
(2008, p274) demonstrates that it is wrong not to share information that 
the individual would find important when there is no compelling reason 
not to do so.  Reasons not to do so might include; participants not 
wanting to know, divulging the information may harm others or breach 
some, other, previous undertaking. 
 The impact that the discovery may have on the participant, their family or 
culture.  The other principle that Miller, Mello & Joffe (2008, p273-274) 
expand on is the rescue principle.  They describe it thus: “if you are 
presented with a situation in which you can prevent something very bad 
from happening, or alleviate someone’s dire plight, by making only a 
slight (or even moderate) sacrifice, then it would be wrong not to do so.”   
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It is easy to imagine how this principle may apply within clinical research.  
However, research within the social science carries with it the prospect of a 
range of relational incidental findings which may occur such as; emotional, 
professional, or social harm.  In such situations, the impact on participants is 
likely to require careful assessment that will be informed by the nature of the 
relationship between them and the researchers. 
 
The relevance of benefits in human research ethics  
One means of promoting beneficence is to emphasise the maximisation of the 
benefits rather than the minimisation of the risks involved in human research. 
This approach is suggested in the Belmont Report (part B.2) but is not adopted 
in the National Statement, which requires the presence of sufficient benefit as 
part of satisfying the value of research merit. HoweverInstead, the National 
Statement, in paragraph 1.7(a) requires investigators to clarify benefits as well 
as to minimize the risks of harm or discomfort to participants: 
 1.7 Researchers are responsible for: 
(a) designing the research to minimize the risks of harm or 
discomfort to participants; 
(b) clarifying for participants the potential benefits and risks of the 
research; and 
(c) the welfare of the participants in the research context. 
It is notable that subparagraph (c) of this paragraph echoes the element of 
doing good that is a part of the traditional meaning of the value of beneficence. 
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Where research has benefit and satisfies the value of research merit, that benefit 
may accrue to participants directly, e.g. as better treatments for their illnesses 
or conditions, indirectly, e.g. as recipients of more effective social welfare 
policies, or not at all. However, as paragraph 1.1(a) of the National Statement 
indicates, there can be exceptions to this, so that  
What constitutes potential benefit and whether it justifies research may 
sometimes require consultation with the relevant communities; 
In Australia, it is increasingly recognised that Aboriginal and Torres Strait 
Islander people are such communities, especially in relation to health and 
medical research.  As a result, the National Statement, in chapter 4.7, explicitly 
addresses the matter of the benefits of research to those communities.  
At the time of prior ethical review, it is only intended benefits that can be 
assessed. However, as a research project progresses, assessments of the 
likelihood of intended benefits - and of predicted risks – can be made more 
accurately. Where this assessment identifies situations where the risks are no 
longer justified, usually because the risks are in fact higher than expected, but 
also if it is apparent that benefits will be less than intended, research is likely to 
need to be suspended. This is recognized by the National Statement in 
paragraph 1.9 and other paragraphs in Chapter 5.5.  
What are the benefits of research? 
At the individual level 
One of the genuine difficulties in making general statements about how to show 
the benefits of research is that each research project that is reviewed is, by its 
nature, unique.  Projects are considered for their adherence to the values and 
principles of the National Statement and researchers are expected to detail any 
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benefits to the individual that arise from the research.  However, there is little 
guidance provided within the National Statement as to what constitutes such a 
benefit.  HREC members must make a judgement on benefits to the individual, 
and therefore, whether these (as well as other broader benefits) are sufficient to 
justify any risks to participants. However, little more is offered to assist 
recognising and defining what “benefit” actually means. 
The US Department of Health and Human Services defines the benefits of 
research as: 
A research benefit is considered to be something of health-related, 
psychosocial, or other value to an individual research subject, or 
something that will contribute to the acquisition of generalizable 
knowledge. – [Gottesman & Sandler: 2004, p24] 
The National Health and Medical Research Council (NHMRC) – Department of 
Industry jointly hosted web-site, Australian Clinical Trials, promotes the 
individual benefits of clinical trials as including: 
 Access to new, possibly better, interventions before they are made 
available to the general public; 
 Clinical trials may also be valuable for people with rare or difficult-to-treat 
conditions for which there may be limited evidence about how the 
condition is best treated or managed; 
 The chance to play an active role in your own health care and gain a 
greater understanding of your disease or condition; 
 Advice, care and support from trained clinical staff who understand your 
disease or condition; and  
 Closer monitoring of your condition, care and treatment. - (CHF, 2013) 
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Confined as they are to a well defined arena of research, these statements fall 
somewhat short of offering assistance in any human research in several ways.  
Firstly, not all research will directly benefit the participant in a tangible way and 
the term “other value” seems to be so broad as to be useless as a point of 
guidance.  Secondly, limiting benefits to findings that can be generalisable is to 
discount qualitative research as not being beneficial.  It is also unclear as to how 
these points differ from good clinical practice.  One benefit which may be derived 
from clinical trials is that, if the research intervention proves to be more 
effective than current standard treatment, participants might come to receive 
the improved treatment. 
It is important that researchers do not over-state the benefits of their project.  
The Consumers Health Forum of Australia warns that “there is no guarantee that 
any individual participant will receive any direct benefit from taking part in a 
trial” – (CHF, 2013).  If the research team over-state the benefits, there is a risk 
that participants may have been “unduly influenced by the expectation, whether 
justified or not, of benefits associated with participation” – (TGA 2000 1.61).  
However, the majority of human research projects conducted are not clinical 
trials.  All researchers have a duty to ensure that they understand the field that 
they are researching sufficiently so that they can foresee likely benefits. 
Researchers must ensure that they clearly demonstrate within the application 
how the principle of beneficence is present in their project.  Without being able 
to specify accurately the good to be gained by the research and/or individual 
participants, there is a risk that people will be seen as just another resource 
available for researchers to exploit and that their involvement in research will be 
unethical. 
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Benefits of qualitative research techniques can be difficult to identify.  There are 
similar claims as those made by quantitative researchers in that the research 
benefits society by making a contribution to knowledge.  Qualitative research 
sometimes claims individual benefit through improved well-being, or 
empowerment of the individual by giving him or her a voice.  Israel and Hay 
(2006) report that studies have found that being heard can be of immense value 
to otherwise disenfranchised participants.  Conversely, in other circumstances, 
such as researching individuals or groups that have survived emotional or 
psychological trauma, there is genuine risk of exacerbating the harm already 
suffered.  It is for researchers to make a case that this risk can be mitigated and 
managed and that there can be benefits in participation. Equally important is 
that the HREC must have the skills and experience to assess researcher claims 
either within its membership or available to it.  
Benefits to research participants help in establishing the justification of risks to 
which they are exposed.  However, not all research does benefit participants, 
nor is it intended to.  Much of the research involved in the social sciences may 
well be detrimental to participants but deliver a wider benefit (Israel & Hay 
2006; Langlois 2011, p150).  Examples of this type of research include studying 
sexual offenders, abuses of power or malpractice. 
Beyond participants: beneficence at a broader level 
Looking at beneficence at the meta-level, rather than at the individual project 
level, may not be helpful to discussion within the ethics committee.  The more 
abstract the benefit, the harder it becomes to include in the risk-benefit analysis.  
Potential benefits to society are difficult to quantify.  There appears to be an 
assumption that research is, inherently, good and that there is a consensus that 
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“progress” is in the interests of society (Jonas p230).  The National Statement 
goes further, stating that “benefit to humankind is an important result of 
research” (p11).  In order to continue to be seen as a societal good, research 
needs to build and maintain the trust of the community that it serves.  By over-
stating the benefits or by obfuscating the risks, researchers harm the trust that 
supports the voluntary nature of human research (NS p7). 
People volunteer to be part of research for many reasons, one of which, is to 
benefit others.  Any research application submitted for the consideration of an 
HREC should clearly demonstrate how that benefit will be evidenced.   If nothing 
is done with the knowledge obtained through research, then these benefits are 
not realised and the ethical basis of the involvement of participants in the 
research endeavour – the benefits of increased or improved knowledge – must 
be questioned.  However, as the risks are often immediate and the supposed 
benefits are often future, there is a great deal of faith placed on the researchers 
to see their proposals through to publication of results.  The dissemination of the 
findings serves several purposes. First, it enables the merit of the research to be 
assessed by exposing the design, conduct and outcomes to public and scholarly 
scrutiny.  Second, it reveals and establishes the benefit of the research. Third, it 
informs participants of results derived from their participation and expresses an 
element of the principle of justice. (National Statement 1.5) This can help 
participants gain a sense of belonging to, or being part of, the benefits of the 
research.  HRECs ought to take into consideration the publication record of 
applicants where the dissemination of findings is promoted as one of the benefits 
to be gained. 
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Reflecting on the Social and Cultural Implications of Research 
Risks beyond participants 
Consideration of potential risks and harms ought to be conducted with a wide 
perspective.  It is not only individual participants that are at risk of harm.  
Unintended harm from research findings can be felt by the families and 
communities of participants.  For example, research into sea side communities’ 
understanding of and planning for the effect of climate change on sea levels can 
lead not only to community anxiety but to negative effects on property values 
and commercial prospects. Other instances of this type of adverse effect include: 
findings that may stigmatise communities or societies in a way that might lead 
to stereotyping or ostracising groups; incidental findings in genetic research that 
can impact on family relationships or on the health status (or perception thereof) 
of family members. 
There is also the potential to harm institutions, particularly harm to an 
organisation’s reputation.  Researchers should be alert to the risk that their 
research could cause inadvertent harm to either their own or some other 
institution.  In some forms of research, for example, where the aim is to expose 
corruption or illegal practice, negative impacts on organisational reputation 
constitute a potential harm that may be justified by a societal good.  However, 
the potential for harm to institutions is not limited to research where the intent 
is to expose wrong-doing.  Any research into institutional practice has the 
potential to expose breaches of duties of care, incompetence, or illegality.  
Despite these foreseeable consequences, these forms of research need not be 
curtailed and they can provide benefits to the wider society as exposure of fraud, 
corruption or poor practice can inform correction and reform.  However, these 
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possible outcomes need to be considered when reflecting on the application of 
beneficence to the project and researchers should, where relevant, include a 
plan to manage these outcomes.   
Vulnerability of participants 
The question of vulnerability of participants is a necessary consideration in 
human research ethics and would typically arise in the context of beneficence.  
The National Statement identifies certain people as being inherently vulnerable 
and, therefore, applications that seek to recruit these people require careful 
examination.  Both researchers and HREC members need to comprehend the 
source of vulnerability for these individuals. Researchers, through their 
relationship, have an obligation for the welfare of participants (National 
Statement, paragraphs 1.7(c)) and to behave in a manner which promotes 
beneficence.  It is through understanding the potential impacts that their 
research might have on these populations that researchers can devise strategies 
that achieve this.  The vulnerability of an individual or group may vary with 
circumstance.  Israel (2014, p135) provides conflicting examples researchers of 
working with victims of violence against women.  He offers the example of one 
research team providing benefits to participants by “acting as a doorway to 
information and brokered referrals to support agencies” and follows this with an 
example of research by Lorraine Nencel where she found this could “lead to a 
process of exclusion” of those women unwilling to cooperate    Without a well-
grounded understanding of the sources and manifestation of vulnerability within 
the participant population, the potential effects of research are difficult to 
evaluate, not only in terms of protecting participants, but also in terms of 
developing resilience and promoting agency (Rogers, Mackenzie & Dodds 2012, 
pp 12-13).   
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When working with individuals, societies or cultures that are vulnerable, the 
principle of beneficence imposes a specific duty on researchers to positively 
promote their well-being.  This is a duty which goes beyond that imposed by 
non-maleficence.  It is a positive duty, to do good.  That being said, Israel 
(2014, pp 130-131) provides plenty of examples where social science 
researchers simply do not have the power to protect, let alone positively benefit, 
the participants of their research. 
One way of mitigating risks to such people and demonstrating positive outcomes 
is to work with the community to develop the research project and the 
methodology to be adopted.  A sound working relationship between researchers 
and vulnerable populations should be evident not only from the commencement 
of the research process, but is especially vital when discussions about 
dissemination of findings are considered.  The National Statement provides a 
warning at paragraph 4.3.6 that in, some circumstances, “[r]esearchers need to 
be mindful that in some relationships of dependency, participants may have an 
unrealistic expectation of the benefits of research.”  This is a genuine risk of 
which researchers may be unaware when designing their project and which 
constructive engagement with the community being researched will help to 
mitigate.  This is a position that is strongly supported within the Guidelines for 
Ethical Research in Australian Indigenous Studies (2102) with the statement 
that: “At every stage, research with and about Indigenous peoples must be 
founded on a process of meaningful engagement and reciprocity between the 
researcher and Indigenous people” (p 3).  Publications and presentations of 
findings must ensure that, wherever possible, those people most affected have 
an understanding of findings before they are made public.  This is especially true 
where the findings may have an adverse effect on these people.  Any research 
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submission that deals with vulnerable groups should be include a statement on 
how possible adverse findings will be managed. 
 
The Value of Conversation 
As is usually the case where a formalised process is built around ethical decision-
making, there is room to improve the deliberations of HRECs.  In our experience, 
one of the most effective measures for developing a deeper understanding of the 
impacts of a proposed human research project is to enter into a conversation 
with the research team.  The earlier this dialogue is begun, the better the 
mutual understanding should be by the time a decision needs to be made.  The 
dialogue ought to be seen as an opportunity to develop mutual understanding; 
the HREC should use it as a way to educate researchers in the expectations of 
the committee while for researchers, it is an opportunity to reflect on the 
implications of their proposal and clarify any issue that may be unclear to the 
committee. 
A current literature review is commonly required as part of the submission 
process.  The importance of this is often under estimated by researchers.  The 
literature review can:  
 demonstrate that the research team is aware of the latest advancements 
in their chosen field; 
 demonstrate that the apparent risks in the proposed research 
methodology have not materialised in comparative projects; 
 help the HREC to educate themselves on the subject matter; and, 
 help HREC members to frame relevant questions to clarify the risks and 
benefits in a particular research project. 
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Researchers should, where possible and ethically important, clearly demonstrate 
that they are actively engaged with the communities that they intend to 
research.  This is particularly important in research that is specific to a particular 
group.  It is important that researchers can demonstrate that they understand 
the culture of a population so that not only are the aspirations of that 
community promoted but also that the researchers are able to identify, manage 
and mitigate risks that are pertinent to that group.  It should not be left to the 
HREC to extrapolate this understanding.  It ought to be explicit within the 
documentation provided in support of the application. 
Just as important as being up to date with the latest thinking in the chosen field 
of research is adding to the body of knowledge.  One very important way that 
researchers can show an HREC the benefit of their research to their community 
is to promulgate their research findings accurately and timeously.  This might be 
done through a combination of paths: 
 Presenting findings to a population that has contributed to the research 
can be a significant benefit for that community; 
 Delivering papers at conferences to educate peers and other interested 
parties helps to improve the depth of understanding of researchers in a 
field of study; 
 Publishing in reputable peer-reviewed journals reaches a wider audience 
and provides a permanent record. 
The more informed the conversation about the ethics of a particular research 
project, the more likely it is that a balanced and meaningful decision can be 
made about the ethical acceptability of the project. 
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Conclusion 
Citizens do not have a general right to beneficence.  As a principle, it should be 
seen as virtuous if demonstrated but not considered to be an entitlement or 
expectation.  However, when people volunteer as participants in human research 
projects it is reasonable for them to expect that some good will eventuate from 
their participation.  Although research involving human participants seeks to 
avoid harm to the participants, sometimes the nature of the research is such 
that harm is unavoidable. For these reasons, it is reasonable to expect that 
every human research project will promote some general good.  Every human 
research proposal ought to be able demonstrate how risks will be mitigated and 
managed and how these are justified by the potential good that is expected to 
come from the project. 
Human research should be seen as a worthwhile endeavour and each piece of 
research should help to promote that view.  By its nature, because human 
research relies on the charity of participants, researchers need to accept a 
responsibility not only for the welfare of participants but also to promote 
beneficence through research that benefits participants and/or the wider 
community.  
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